Updates on Paget's Disease of Bone

• Published in: Endocrinology and metabolism (Seoul) Vol. 37; no. 5; pp. 732 - 743
• Main Authors: Choi, Yong Jun, Sohn, Young Bae, Chung, Yoon-Sok
• Format: Journal Article
• Language: English
• Published: Korea (South) Korean Endocrine Society 01-10-2022
• Subjects: bisphosphonates; Bone and Bones - diagnostic imaging; Bone Resorption - complications; Bone Resorption - drug therapy; Diphosphonates - therapeutic use; genetics; Humans; Osteitis Deformans - diagnosis; Osteitis Deformans - drug therapy; Osteitis Deformans - etiology; paget’s disease of bone; Pamidronate - therapeutic use; Review; Genetics; Bisphosphonates; Paget’s disease of bone
• ISSN: 2093-596X; 2093-5978
• DOI: 10.3803/EnM.2022.1575

Paget's disease of the bone is a prevalent bone disease characterized by disorganized bone remodeling; however, it is comparatively uncommon in East Asian countries, including China, Japan, and Korea. The exact cause still remains unknown. In genetically susceptible individuals, environmental triggers such as paramyxoviral infections are likely to cause the disease. Increased osteoclast activity results in increased bone resorption, which attracts osteoblasts and generates new bone matrix. Fast bone resorption and formation lead to the development of disorganized bone tissue. Increasing serum alkaline phosphatase or unique radiographic lesions may serve as the diagnostic indicators. Common symptoms include bone pain, bowing of the long bones, an enlarged skull, and hearing loss. The diagnosis is frequently confirmed by radiographic and nuclear scintigraphy of the bone. Further, bisphosphonates such as zoledronic acid and pamidronate are effective for its treatment. Moreover, biochemical monitoring is superior to the symptoms as a recurrence indicator. This article discusses the updates of Paget's disease of bone with a clinical case.